Hyderabad: All documents needed for the Emergency use list (EUL) of the original Covid vaccine developed.
Covaxin has been submitted to the World Health Organization (WHO), the development of the Chair and Managing Director of Bharat Biotech, Dr.
Krishna Ella said on Monday.
He said this marked the beginning of the review process for vaccines.
Desi Vaksin Covid-19 has demonstrated the efficacy of 77.8% in accordance with the analysis of the final phase data published by the company earlier this month.
“All the documents needed for the EUL of Covaxin have been handed over to the WHO on July 9.
The review process has now begun in the hope that we will receive EUL from the earliest,” said statement by Dr.
Ella Tweet from the official Twitter handle Bharat Biotech.
Who had received the company’s interest expression (EOI) for Covaxin in mid-June.
During the weekend, who the Head of Scientist Sowmya Swaminathan has indicated that Bharat Biotech has submitted complete data and a global health body is expected to make decisions about EUL for the next four to six weeks.
Managing Director with Bharat Biotech Suchitra Ella also recently tweeted about this.
“Covaxin will cross the new border, comply with the highest international regulatory guidelines.
The new vaccine from India is ready to make history once again, with data, safety & quality that is proven,” he said.
A WHO NOD will be the main booster shot for Covaxin because it will provide global acceptance and easing international tourist concerns about not allowed in.